refractory membranous nephropathy
Conditions
Interventions
Trial group:Standardized treatment combined with intravenous transfusion of umbilical cord blood-derived mononuclear cells
Control group:Standardized treatment with corticosteroids and immunosuppressants
Sponsors
Tai'an Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18 years old. Renal biopsy pathologically confirmed membranous nephropathy or elevated serological anti-phospholipase A2 receptor antibody titers; (2) Patients who have received first-line immunosuppressant therapy such as steroids, cyclophosphamide, and tacrolimus for 3 months, and have not achieved partial or complete response; (3) Patients with positive anti-PLA2R antibody persisted serum anti-PLA2R antibody (not negative or improved) after receiving immunosuppressive therapy; (4) Patients who voluntarily participate in the study and sign informed consent; (5) Patients who are willing and able to carry out treatment and follow-up according to the requirements of the protocol, and can follow the doctor's instructions for basic treatment.
Exclusion criteria
Exclusion criteria: (1) eGFR<30 ml·min?¹·(1.73 m²)?¹; (2) Patients with secondary membranous nephropathy; (3) Patient with active hepatitis; (4) Patients with malignant tumors, severe infections, tuberculosis and dysfunction of organs such as heart, lung, and liver; (5) Patients with mental illness who cannot cooperate with treatment; (6) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urinary protein quantification;Serum albumin;Gomerular filtration rate;Serum anti-PLA2R antibody; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;Blood lipids;Routine urine test;IgG, IgA, IgM, serum cytokines, and lymphocyte subsets; | — |
Countries
China
Contacts
Public ContactWang Liya
Tai'an Central Hospital
Outcome results
None listed